MEDICAL POLICY

SUBJECT: PROLOTHERAPY

POLICY NUMBER: 8.01.10
CATEGORY: Technology Assessment

EFFECTIVE DATE: 09/16/99
REVISED DATE: 05/01/00, 09/19/01, 07/18/02, 09/18/03, 06/17/04, 03/17/05, 03/16/06, 03/15/07, 02/21/08, 01/15/09, 10/29/09, 10/28/10, 09/15/11
ARCHIVED DATE: 09/20/12
EDITED DATE: 09/19/13, 09/18/14

• If the member’s subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
• Medical policies apply to commercial and Medicaid products only when a contract benefit for the specific service exists.
• Medical policies only apply to Medicare products when a contract benefit exists and where there are no National or Local Medicare coverage decisions for the specific service.

POLICY STATEMENT:

Based on our criteria and assessment of the peer-reviewed literature, prolotherapy has not been medically proven to be effective and is considered investigational as a treatment of musculoskeletal pain.

Effective June 1, 2012, Managed Medicaid and Family Health Plus no longer covers prolotherapy as a treatment for low back pain.

Refer to Corporate Medical Policy #11.01.03 regarding Experimental and Investigational Services.

POLICY GUIDELINES:

The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION:

Prolotherapy describes a procedure for healing and strengthening lax ligaments by injecting proliferating agents/sclerosing solutions directly into torn or stretched ligaments. “Proliferatives” act to promote tissue repair or growth by prompting release of growth factors, such as cytokines, or increasing the effectiveness of existing circulating growth factors. Agents used with prolotherapy have included zinc sulfate, psyllium seed oil, combinations of dextrose, glycercine phenol, Sarapin or dextrose alone. Polidocanol and sodium morrhuate, vascular scleroscants, have also been utilized to sclerose areas of high intratendinous blood flow associated with tendinopathies. Prolotherapy has been investigated as a treatment of various etiologies of pain, including arthritis, degenerative disc disease, fibromyalgia, tendonitis, and plantar fasciitis. Prolotherapy may involve a single injection or a series of injections, often diluted with a local anesthetic. Prolotherapy may also be referred to proliferant injection, joint sclerotherapy, regenerative injection therapy, or nonsurgical tendon, ligament and joint reconstruction.

RATIONALE:

Although individual ingredients such as dextrose and lidocaine are approved for injection by the FDA, they are not approved for prolotherapy. Drug solutions injected during prolotherapy are typically prepared by compound pharmacies or individual practitioners, and therefore are not subject to regulation by the FDA.

Scientific data demonstrating the effectiveness of prolotherapy for the treatment of joint and ligament instability is limited and interpretation complicated by variations in treatment protocols, the use of concomitant treatments, and lack of a non-injection control group. As with any therapy for pain, a placebo effect is anticipated and therefore randomized placebo-controlled trials are necessary to investigate the extent of the placebo effect and to determine whether any improvement with prolotherapy exceeds that associated with a placebo. In the two clinical trials referenced (both by Reeves), it is not known whether the incremental improvement in the non-pain-related outcomes of the prolotherapy group compared to the control group is clinically significant. The clinical significance of an isolated finding of improved flexion without a corresponding significant improvement in pain is uncertain. Additional studies with larger control and

Proprietary Information of Excellus Health Plan, Inc.
experimental groups must be conducted to evaluate the efficacy of prolotherapy for joint or ligament instability. There is inadequate evidence of the effectiveness of Sarapin for pain.

**CODES:**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0076 (E/I)</td>
<td>Prolotherapy</td>
</tr>
<tr>
<td>724.2</td>
<td>Pain, lower back</td>
</tr>
<tr>
<td>724.4</td>
<td>Thoracic or lumbosacral neuritis or radiculitis, unspecified</td>
</tr>
<tr>
<td>M51.14-M51.17</td>
<td>Intervertebral disc disorders with radiculopathy (code range)</td>
</tr>
<tr>
<td>M54.14-M54.17</td>
<td>Radiculopathy (code range)</td>
</tr>
<tr>
<td>M545</td>
<td>Low back pain</td>
</tr>
</tbody>
</table>

**REFERENCES:**


KEY WORDS:
Proliferating agent, Prolotherapy, Sarapin, Sclerosing.

---

**CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS**

There is currently a National Coverage Determination (NCD) for prolotherapy. Please refer to the following NCD website for Medicare Members: http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=15&ncdver=1&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=New+York+-+Upstate&CptHcpcsCode=36514&bc=gAAAABAAAAAA&

Proprietary Information of Excellus Health Plan, Inc.